Emanuela Cuomo is an Associate Director in the Discovery Biology department in AstraZeneca, Cambridge. She leads the Cell Biology team that generates cell models for target identification and validation for Oncology. One of her main interest is the study of mechanisms of resistance to targeted therapies. She leads the DB UK Precise genome editing discipline contributing to innovation in CRISPR and base editing technologies.
Emanuela is an expert in the study of cell cycle signaling in normal and cancer cells. She obtained a PhD in biochemistry at the Institute of Cancer Research in London where she characterised a novel viral cyclin/CDK complex, its modulation by CDK inhibitors and its biological function in oncogenesis. Subsequently she joined UCL Cancer Institute in London in the Viral Oncogenesis team as a CR-UK postdoctoral fellow. There, she studied the interplay between the cellular DNA damage response and viral protein kinases.